Sept. 01, 2015

ZEISS Sets the Pace in OCT Innovation with First FDA 510(k) Clearance of OCT Angiography Technology

AngioPlex OCT Angiography from ZEISS is the next generation of vascular imaging, providing non-invasive 3D images of blood flow in the eye to help eye care professionals detect retinal diseases earlier and improve treatment and management of these diseases


DUBLIN, CA USA

ZEISS Medical Technology announces that its AngioPlex OCT Angiography is the first such technology to receive 510(k) clearance from the U.S. Food and Drug Administration (FDA).

With a single additional OCT scan that takes just seconds on the CIRRUS HD-OCT system from ZEISS, ophthalmologists can now utilize optical coherence tomography (OCT) images to assess the blood vessels (vasculature) of the retina at a depth and clarity never available before. AngioPlex OCT Angiography delivers high-resolution, depth-resolved visualization of the separate layers of the retinal and choroidal vasculature -- without the need for an injected contrast dye, as is standard with fluorescein angiography (FA).

The information provided by these images is clinically impactful, because progression of retinal diseases is often accompanied by changes in the vasculature of the eye. In age-related macular degeneration (AMD), diabetic retinopathy, central retinal vein occlusion and other vascular conditions, AngioPlex OCT Angiography can complement traditional FA and become a safe and efficient part of routine eye care, potentially enabling earlier detection and management of micro-progressions.

“OCT angiography ushers in a new era in the evaluation of the retina in diabetic retinopathy and macular degeneration,” said Carmen Puliafito, MD, dean of the Keck School of Medicine at the University of Southern California and one of the co-inventors of OCT. “Retinal specialists will now be able to obtain high-resolution cross-sectional images of the macula coupled to the most detailed visualization of the retinal vasculature ever achieved. This unique capability promises to revolutionize clinical decision making in retinal pharmacotherapy.”

AngioPlex OCT Angiography clearly visualizes blood flow by detecting motion of scattering particles, such as red blood cells, within sequential OCT B-scans performed repeatedly at the same location of the retina. Unlike other OCT angiography systems that require multiple OCT scans to generate one single OCT angiography image, CIRRUS HD-OCT with AngioPlex only requires a single additional OCT scan. The key to this is the real-time retinal tracking system, FastTrac™, which actively eliminates eye motion to provide motion-artifact-free images of the perfused retina. Equally important, FastTrac enables follow-up OCT angiography images to be acquired at the same precise location in order to assess treatment efficacy and monitor disease progression.

In addition, AngioPlex is powered by Optical Micro Angiography (OMAG) Algorithms to provide ultra-clear vascular images. OMAG is an image processing technique that takes full advantage of not only amplitude but also phase OCT signal data to deliver the highest-quality OCT angiography images.

AngioPlex OCT Angiography is available on the CIRRUS 5000 HD-OCT platform , allowing ophthalmic practices the flexibility to easily integrate vascular imaging with standard OCT diagnostic imaging.

“We are pleased to provide U.S. doctors with a single OCT solution that allows them to make this revolutionary technology part of their daily clinical practice,” said Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. “As the first such system cleared in the U.S., AngioPlex OCT Angiography continues a long tradition of ZEISS delivering innovations that help improve clinical decision-making and, ultimately, outcomes for patients.”

In addition to FDA clearance of AngioPlex, CE Marking is pending from the European Union.

Press contact
Bill Taggart, Group Communications, Carl Zeiss Meditec, Inc.
Dublin, California
Mobile +1 925-493-9251;
Email: william .taggart @zeiss .com

Jann Gerrit Ohlendorf, Group Communications, Carl Zeiss Meditec AG
Phone +49 (0) 3641 220-331,
Email: press .meditec @zeiss .com


For investors
Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG
Phone +49 (0) 3641 220-116,
Email: investors .meditec @zeiss .com


www.meditec.zeiss.com/press

Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG
Phone +49 (0) 3641 220-116,
Email: investors .meditec @zeiss .com


www.meditec.zeiss.com/press

We use cookies on this site. Cookies are small text files that are stored on your computer by websites. Cookies are widely used and help to optimize the pages that you view. By using this site, you agree to their use. more